Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143466 · ClinicalTrials.gov registry record · Phase 1
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
A Phase 1 study of Advanced Non-Small-Cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 344
- Enrollment target
- 20
- Study locations
NCT02143466 is a Phase 1 study of Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 344 participants, roughly in line with the 367-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT02143466, a Phase 1 study of Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 344 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
Conditions Studied
Interventions
- DRUG Part A - AZD9291 in combination with AZD6094
- DRUG Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)
- DRUG Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
- DRUG Part A - AZD9291 in combination with intermittent selumetinib
- DRUG Part A - AZD9291 in combination with MEDI4736
Study Locations (20)
Other
- Research Site - Chūōku
- Research Site - Habikino-shi
- Research Site - Hirakata-shi
- Research Site - Kashiwa
- Research Site - Nagoya
- Research Site - Nagoya
- Research Site - Gdansk
- Research Site - Krakow
- Research Site - Olsztyn
- Research Site - Poznan
- Research Site - Warsaw
- Research Site - Chelyabinsk
Massachusetts
- Research Site - Boston
- Research Site - Boston
Alberta
- Research Site - Calgary
- Research Site - Edmonton
Georgia
- Research Site - Atlanta
New York
- Research Site - New York
Pennsylvania
- Research Site - Philadelphia
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2014-08-05 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143466
The ClinicalTrials.gov registry entry for NCT02143466 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 367-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Part A - AZD9291 in combination with AZD6094 is the first listed.
NCT02143466 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Massachusetts, Alberta.
Frequently Asked Questions
What is clinical trial NCT02143466 about?
NCT02143466 is a clinical study titled "AZD9291 in Combination With Ascending Doses of Novel Therapeutics". The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
What is the current status of trial NCT02143466?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 344 participants. The study started on 2014-08-05. Estimated completion is 2026-12-31.
What conditions does trial NCT02143466 study?
This clinical trial studies the following conditions: Advanced Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT02143466?
The interventions under investigation include: Part A - AZD9291 in combination with AZD6094 (DRUG), Part A - AZD9291 in combination with continuous selumetinib (Asian subjects) (DRUG), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects) (DRUG), Part A - AZD9291 in combination with intermittent selumetinib (DRUG), Part A - AZD9291 in combination with MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02143466?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02143466 being conducted?
This trial has 20 study locations across Georgia, Massachusetts, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
ACTIVE NOT RECRUITING · Phase 1
-
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants
COMPLETED · Phase 1
-
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.